Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Operating Expenses (2020 - 2025)

Historic Operating Expenses for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $130.4 million.

  • Mirum Pharmaceuticals' Operating Expenses rose 2653.38% to $130.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $513.6 million, marking a year-over-year increase of 2744.14%. This contributed to the annual value of $424.5 million for FY2024, which is 4363.92% up from last year.
  • According to the latest figures from Q3 2025, Mirum Pharmaceuticals' Operating Expenses is $130.4 million, which was up 2653.38% from $132.8 million recorded in Q2 2025.
  • In the past 5 years, Mirum Pharmaceuticals' Operating Expenses ranged from a high of $132.8 million in Q2 2025 and a low of $45.6 million during Q1 2022
  • In the last 5 years, Mirum Pharmaceuticals' Operating Expenses had a median value of $62.1 million in 2022 and averaged $79.5 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first soared by 12022.47% in 2021, then crashed by 416.9% in 2022.
  • Over the past 5 years, Mirum Pharmaceuticals' Operating Expenses (Quarter) stood at $48.7 million in 2021, then rose by 27.41% to $62.1 million in 2022, then soared by 64.56% to $102.1 million in 2023, then increased by 21.05% to $123.6 million in 2024, then grew by 5.48% to $130.4 million in 2025.
  • Its Operating Expenses was $130.4 million in Q3 2025, compared to $132.8 million in Q2 2025 and $126.8 million in Q1 2025.